175 related articles for article (PubMed ID: 22303974)
1. QSAR applications during last decade on inhibitors of acetylcholinesterase in Alzheimer's disease.
Wong KY; Duchowicz PR; Mercader AG; Castro EA
Mini Rev Med Chem; 2012 Sep; 12(10):936-46. PubMed ID: 22303974
[TBL] [Abstract][Full Text] [Related]
2. 2D & 3D-QSAR Study on Novel Piperidine and Piperazine Derivatives as Acetylcholinesterase Enzyme Inhibitors.
Nazari M; Tabatabai SA; Rezaee E
Curr Comput Aided Drug Des; 2018; 14(4):391-397. PubMed ID: 30047333
[TBL] [Abstract][Full Text] [Related]
3. Computational Studies on Acetylcholinesterase Inhibitors: From Biochemistry to Chemistry.
Bagri K; Kumar A; Manisha ; Kumar P
Mini Rev Med Chem; 2020; 20(14):1403-1435. PubMed ID: 31884928
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Acetylcholinesterase (AChE): A Potential Therapeutic Target to Treat Alzheimer's Disease.
Li Y; Zhang XX; Jiang LJ; Yuan L; Cao TT; Li X; Dong L; Li Y; Yin SF
Chem Biol Drug Des; 2015 Oct; 86(4):776-82. PubMed ID: 25736722
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease.
Son M; Park C; Rampogu S; Zeb A; Lee KW
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823604
[TBL] [Abstract][Full Text] [Related]
6. QSAR studies on N-aryl derivative activity towards Alzheimer's disease.
Solomon KA; Sundararajan S; Abirami V
Molecules; 2009 Apr; 14(4):1448-55. PubMed ID: 19384276
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer's Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches.
Pang X; Fu H; Yang S; Wang L; Liu AL; Wu S; Du GH
Molecules; 2017 Jul; 22(8):. PubMed ID: 28933746
[TBL] [Abstract][Full Text] [Related]
8. A comparative QSAR analysis of acetylcholinesterase inhibitors currently studied for the treatment of Alzheimer's disease.
Recanatini M; Cavalli A; Hansch C
Chem Biol Interact; 1997 Aug; 105(3):199-228. PubMed ID: 9291997
[TBL] [Abstract][Full Text] [Related]
9. A combinatorial feature selection approach to describe the QSAR of dual site inhibitors of acetylcholinesterase.
Asadabadi EB; Abdolmaleki P; Barkooie SM; Jahandideh S; Rezaei MA
Comput Biol Med; 2009 Dec; 39(12):1089-95. PubMed ID: 19854437
[TBL] [Abstract][Full Text] [Related]
10. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B; Singh N
Bioorg Med Chem; 2012 Feb; 20(3):1175-80. PubMed ID: 22257528
[TBL] [Abstract][Full Text] [Related]
11. 3D-QSAR analysis of a new type of acetylcholinesterase inhibitors.
Liu A; Guang H; Zhu L; Du G; Lee SM; Wang Y
Sci China C Life Sci; 2007 Dec; 50(6):726-30. PubMed ID: 17914643
[TBL] [Abstract][Full Text] [Related]
12. Construction of the pharmacophore model of acetylcholinesterase inhibitor.
Zhu Y; Tong XY; Zhao Y; Chen H; Jiang FC
Yao Xue Xue Bao; 2008 Mar; 43(3):267-76. PubMed ID: 18630262
[TBL] [Abstract][Full Text] [Related]
13. Combined 3D-QSAR, molecular docking, and molecular dynamics study of tacrine derivatives as potential acetylcholinesterase (AChE) inhibitors of Alzheimer's disease.
Zhou A; Hu J; Wang L; Zhong G; Pan J; Wu Z; Hui A
J Mol Model; 2015 Oct; 21(10):277. PubMed ID: 26438408
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents.
Ambure P; Kar S; Roy K
Biosystems; 2014 Feb; 116():10-20. PubMed ID: 24325852
[TBL] [Abstract][Full Text] [Related]
15. Quantifying ligand-receptor interactions for gorge-spanning acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Martis EA; Chandarana RC; Shaikh MS; Ambre PK; D'Souza JS; Iyer KR; Coutinho EC; Nandan SR; Pissurlenkar RR
J Biomol Struct Dyn; 2015; 33(5):1107-25. PubMed ID: 24905476
[TBL] [Abstract][Full Text] [Related]
16. Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection.
Singh M; Kaur M; Kukreja H; Chugh R; Silakari O; Singh D
Eur J Med Chem; 2013; 70():165-88. PubMed ID: 24148993
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease.
Zhou LY; Zhu Y; Jiang YR; Zhao XJ; Guo D
Bioorg Med Chem Lett; 2017 Sep; 27(17):4180-4184. PubMed ID: 28751142
[TBL] [Abstract][Full Text] [Related]
18. Xanthone: Potential Acetylcholinesterase Inhibitor for Alzheimer's Disease Treatment.
Vanessa VV; Mah SH
Mini Rev Med Chem; 2021; 21(17):2507-2529. PubMed ID: 33583373
[TBL] [Abstract][Full Text] [Related]
19. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease.
Rees TM; Brimijoin S
Drugs Today (Barc); 2003 Jan; 39(1):75-83. PubMed ID: 12669110
[TBL] [Abstract][Full Text] [Related]
20. Ligand-based 3D-QSAR studies of physostigmine analogues as acetylcholinesterase inhibitors.
Ul-Haq Z; Mahmood U; Jehangir B
Chem Biol Drug Des; 2009 Dec; 74(6):571-81. PubMed ID: 19843075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
